Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors

Por Asher, Nethanel, Marom, Edith M., Ben‐Betzalel, Guy, Baruch, Erez Nissim, Steinberg‐Silman, Yael, Schachter, Jacob, Shapira‐Frommer, Ronnie, Markel, Gal
Publicado no Oncologist (2019)

Nicotinamide Inhibits Vasculogenic Mimicry, an Alternative Vascularization Pathway Observed in Highly Aggressive Melanoma

Por Itzhaki, Orit, Greenberg, Eyal, Shalmon, Bruria, Kubi, Adva, Treves, Avraham J., Shapira-Frommer, Ronnie, Avivi, Camilla, Ortenberg, Rona, Ben-Ami, Eytan, Schachter, Jacob, Besser, Michal J., Markel, Gal
Publicado em 2013

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

Por Ledermann, Jonathan A, Harter, Philipp, Gourley, Charlie, Friedlander, Michael, Vergote, Ignace, Rustin, Gordon, Scott, Clare, Meier, Werner, Shapira-Frommer, Ronnie, Safra, Tamar, Matei, Daniela, Fielding, Anitra, Bennett, Bryan, Parry, David, Spencer, Stuart, Mann, Helen, Matulonis, Ursula
Publicado no Br J Cancer (2016)

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation

Por Kaufman, Bella, Shapira-Frommer, Ronnie, Schmutzler, Rita K., Audeh, M. William, Friedlander, Michael, Balmaña, Judith, Mitchell, Gillian, Fried, Georgeta, Stemmer, Salomon M., Hubert, Ayala, Rosengarten, Ora, Steiner, Mariana, Loman, Niklas, Bowen, Karin, Fielding, Anitra, Domchek, Susan M.
Publicado no J Clin Oncol (2015)

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Por Domchek, Susan M, Aghajanian, Carol, Shapira-Frommer, Ronnie, Schmutzler, Rita K, Audeh, M William, Friedlander, Michael, Balmaña, Judith, Mitchell, Gillian, Fried, Georgeta, Stemmer, Salomon M, Hubert, Ayala, Rosengarten, Ora, Loman, Niklas, Robertson, Jane D, Mann, Helen, Kaufman, Bella
Publicado no Gynecol Oncol (2015)

FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis

Por Levanon, Keren, Sapoznik, Stav, Bahar-Shany, Keren, Brand, Hadar, Shapira-Frommer, Ronnie, Korach, Jacob, Hirsch, Michelle S., Roh, Michael H., Miron, Alexander, Liu, Joyce F., Vena, Natalie, Ligon, Azra H., Fotheringham, Susan, Bailey, Dyane, Flavin, Richard J., Birrer, Michael J., Drapkin, Ronny I.
Publicado em 2013

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

Por Rafii, Saeed, Gourley, Charlie, Kumar, Rajiv, Geuna, Elena, Ang, Joo Ern, Rye, Tzyvia, Chen, Lee-May, Shapira-Frommer, Ronnie, Friedlander, Michael, Matulonis, Ursula, Greve, Jacques De, Oza, Amit M., Banerjee, Susana, Rhoda Molife, L., Gore, Martin E., Kaye, Stan B., Yap, Timothy A.
Publicado no Oncotarget (2017)

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules fol...

Por Friedlander, Michael, Matulonis, Ursula, Gourley, Charlie, du Bois, Andreas, Vergote, Ignace, Rustin, Gordon, Scott, Clare, Meier, Werner, Shapira-Frommer, Ronnie, Safra, Tamar, Matei, Daniela, Shirinkin, Vadim, Selle, Frédéric, Fielding, Anitra, Lowe, Elizabeth S., McMurtry, Emma L., Spencer, Stuart, Rowe, Philip, Mann, Helen, Parry, David, Ledermann, Jonathan
Publicado no Br J Cancer (2018)

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Por Moschos, Stergios J., Sullivan, Ryan J., Hwu, Wen-Jen, Ramanathan, Ramesh K., Adjei, Alex A., Fong, Peter C., Shapira-Frommer, Ronnie, Tawbi, Hussein A., Rubino, Joseph, Rush, Thomas S., Zhang, Da, Miselis, Nathan R., Samatar, Ahmed A., Chun, Patrick, Rubin, Eric H., Schiller, James, Long, Brian J., Dayananth, Priya, Carr, Donna, Kirschmeier, Paul, Bishop, W. Robert, Deng, Yongqi, Cooper, Alan, Shipps, Gerald W., Moreno, Blanca Homet, Robert, Lidia, Ribas, Antoni, Flaherty, Keith T.
Publicado no JCI Insight (2018)